Reshma Shringarpure

7.8k total citations · 2 hit papers
72 papers, 4.9k citations indexed

About

Reshma Shringarpure is a scholar working on Epidemiology, Molecular Biology and Hematology. According to data from OpenAlex, Reshma Shringarpure has authored 72 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Epidemiology, 26 papers in Molecular Biology and 19 papers in Hematology. Recurrent topics in Reshma Shringarpure's work include Liver Disease Diagnosis and Treatment (28 papers), Multiple Myeloma Research and Treatments (17 papers) and Ubiquitin and proteasome pathways (10 papers). Reshma Shringarpure is often cited by papers focused on Liver Disease Diagnosis and Treatment (28 papers), Multiple Myeloma Research and Treatments (17 papers) and Ubiquitin and proteasome pathways (10 papers). Reshma Shringarpure collaborates with scholars based in United States, United Kingdom and France. Reshma Shringarpure's co-authors include Kelvin J.A. Davies, Tilman Grune, Teru Hideshima, Kenneth C. Anderson, Dharminder Chauhan, Nicholas Mitsiades, Constantine S. Mitsiades, Nikhil C. Munshi, Jana Mehlhase and Klaus Podar and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Reshma Shringarpure

69 papers receiving 4.8k citations

Hit Papers

Safety and efficacy of once-weekly efruxifermin versus pl... 2023 2026 2024 2025 2023 2025 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
    2023 146 citations Stephen A. Harrison, Juan P. Frías et al. ˜The œLancet. Gastroenterology & hepatology profile →
  2. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
    2025 19 citations Mazen Noureddin, Mary E. Rinella et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Reshma Shringarpure United States 35 2.9k 1.2k 1.0k 1.0k 671 72 4.9k
Andrew N. Billin United States 38 3.7k 1.3× 810 0.7× 920 0.9× 187 0.2× 301 0.4× 77 5.2k
P D Berk United States 32 2.0k 0.7× 508 0.4× 727 0.7× 540 0.5× 418 0.6× 68 4.1k
William A. Gaarde United States 30 2.4k 0.8× 812 0.7× 905 0.9× 127 0.1× 658 1.0× 41 4.5k
Norman C.W. Wong Canada 42 2.9k 1.0× 495 0.4× 701 0.7× 399 0.4× 173 0.3× 144 5.5k
Heidi S. Camp United States 27 2.4k 0.8× 791 0.7× 614 0.6× 573 0.6× 182 0.3× 74 4.7k
Camilla Evangelisti Italy 38 4.5k 1.5× 499 0.4× 1.4k 1.4× 1.1k 1.0× 488 0.7× 90 6.4k
Gösta Eggertsen Sweden 39 1.5k 0.5× 726 0.6× 1.5k 1.5× 191 0.2× 214 0.3× 115 4.5k
Frédéric Bost France 37 4.8k 1.6× 939 0.8× 1.5k 1.4× 126 0.1× 503 0.7× 95 6.7k
Chieko Mineo United States 44 3.6k 1.2× 623 0.5× 680 0.7× 245 0.2× 1.6k 2.5× 106 7.7k
Thomas Gelehrter United States 39 2.3k 0.8× 221 0.2× 427 0.4× 1.0k 1.0× 360 0.5× 106 4.7k

Countries citing papers authored by Reshma Shringarpure

Since Specialization
Citations

This map shows the geographic impact of Reshma Shringarpure's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reshma Shringarpure with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reshma Shringarpure more than expected).

Fields of papers citing papers by Reshma Shringarpure

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reshma Shringarpure. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reshma Shringarpure. The network helps show where Reshma Shringarpure may publish in the future.

Co-authorship network of co-authors of Reshma Shringarpure

This figure shows the co-authorship network connecting the top 25 collaborators of Reshma Shringarpure. A scholar is included among the top collaborators of Reshma Shringarpure based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reshma Shringarpure. Reshma Shringarpure is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Harrison, Stephen A., Juan P. Frías, Kathryn Jean Lucas, et al.. (2024). Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clinical Gastroenterology and Hepatology. 23(1). 103–113. 37 indexed citations
3.
Carr, Rotonya M., Yun Li, Lillian Chau, et al.. (2023). An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations. Hepatology. 78(6). 1843–1857. 16 indexed citations
4.
Harrison, Stephen A., Juan P. Frías, Guy Neff, et al.. (2023). Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. ˜The œLancet. Gastroenterology & hepatology. 8(12). 1080–1093. 146 indexed citations breakdown →
5.
Harrison, Stephen A., Peter Ruane, B. Freilich, et al.. (2022). A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Reports. 5(1). 100563–100563. 72 indexed citations
6.
Rinella, Mary E., Jean‐François Dufour, Quentin M. Anstee, et al.. (2021). Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. Journal of Hepatology. 76(3). 536–548. 122 indexed citations
7.
Younossi, Zobair M., Vlad Ratziu, Rohit Loomba, et al.. (2019). OTU-14 Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH. A108.2–A108. 9 indexed citations
8.
Ratziu, Vlad, Arun J. Sanyal, Rohit Loomba, et al.. (2019). REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemporary Clinical Trials. 84. 105803–105803. 106 indexed citations
9.
Chalasani, Naga, Manal F. Abdelmalek, Rohit Loomba, et al.. (2018). Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH. PubMed Central. 6 indexed citations
10.
Jones, Michael, William D. Chey, Sandeep Kumar Singh, et al.. (2014). A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Alimentary Pharmacology & Therapeutics. 39(4). 426–437. 55 indexed citations
11.
Hauenstein, Scott, Linda Ohrmund, Reshma Shringarpure, et al.. (2013). Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. Journal of Pharmaceutical and Biomedical Analysis. 78-79. 39–44. 74 indexed citations
12.
Mitsiades, Constantine S., Nicholas Mitsiades, Ciaran J. McMullan, et al.. (2004). Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 5(3). 221–230. 470 indexed citations
13.
Tai, YT, Klaus Podar, Reshma Shringarpure, et al.. (2003). Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3-kinase/AKT signaling beta.. Blood. 102(11). 33 indexed citations
14.
Shringarpure, Reshma, D Chauhan, Renate Burger, et al.. (2003). Gene expression analysis of tumor cells sensitive and resistant to PS-341 (Bortezomib) treatment: Clinical implications.. Blood. 102(11). 1 indexed citations
15.
Burger, Renate, Frank Bakker, Andreas Guenther, et al.. (2003). Functional significance of novel neurotrophin‐1/B cell‐stimulating factor‐3 (cardiotrophin‐like cytokine) for human myeloma cell growth and survival. British Journal of Haematology. 123(5). 869–878. 29 indexed citations
16.
LeBlanc, Richard, Teru Hideshima, Tateki Hayashi, et al.. (2002). Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway.. Blood. 100(11). 1 indexed citations
17.
Shringarpure, Reshma & Kelvin J.A. Davies. (2002). Protein turnover by the proteasome in aging and disease. Free Radical Biology and Medicine. 32(11). 1084–1089. 186 indexed citations
18.
Shringarpure, Reshma, Tilman Grune, Jana Mehlhase, & Kelvin J.A. Davies. (2002). Ubiquitin Conjugation Is Not Required for the Degradation of Oxidized Proteins by Proteasome. Journal of Biological Chemistry. 278(1). 311–318. 358 indexed citations
19.
Shringarpure, Reshma, Tilman Grune, & Kelvin J.A. Davies. (2001). Protein oxidation and 20S proteasome-dependent proteolysis in mammalian cells. Cellular and Molecular Life Sciences. 58(10). 1442–1450. 173 indexed citations
20.
Shringarpure, Reshma, Tilman Grune, Nicolle Sitte, & Kelvin J.A. Davies. (2000). 4-Hydroxynonenal-modified amyloid-β peptide inhibits the proteasome: possible importance in Alzheimer’s disease*. Cellular and Molecular Life Sciences. 57(12). 1802–1809. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew N. Billin Breakdown of academic impact, for papers by P D Berk Breakdown of academic impact, for papers by William A. Gaarde Breakdown of academic impact, for papers by Norman C.W. Wong Breakdown of academic impact, for papers by Heidi S. Camp Breakdown of academic impact, for papers by Camilla Evangelisti Breakdown of academic impact, for papers by Gösta Eggertsen Breakdown of academic impact, for papers by Frédéric Bost Breakdown of academic impact, for papers by Chieko Mineo Breakdown of academic impact, for papers by Thomas Gelehrter
Rankless by CCL
2026